Regeneron Pharmaceuticals (REGN) financial statements

+5914.9%since 2008
FY2025 revenue
$14.3B▲ +1.0%
FY2025 net income
$4.5B▲ +2.1%
FY2025 diluted EPS
$41.48▲ +8.2%
FY2025 free cash flow
$4.1B▲ +11.3%

Regeneron Pharmaceuticals income statement

Regeneron Pharmaceuticals income statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Revenue14,34314,20213,117
Operating income3,5783,9914,047
Pretax income5,2314,7804,199
Net income4,5054,4133,954
Diluted earnings per share41.4838.3434.77

Regeneron Pharmaceuticals balance sheet

Regeneron Pharmaceuticals balance sheet
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Cash and cash equivalents3,1182,4892,730
Total assets40,55937,75933,080
Total liabilities9,3028,4067,107
Total equity31,25729,35425,973
Long-term debt1,9861,9841,983

Regeneron Pharmaceuticals cash flow statement

Regeneron Pharmaceuticals cash flow statement
USD millionsFY2025FY2024FY2023
Period ended31 Dec 202531 Dec 202431 Dec 2023
Operating cash flow4,9794,4214,594
Capital expenditure-898-756-719
Free cash flow (derived)4,0813,6653,875
Dividends paid-37000
Share repurchases-3,439-2,603-2,235

Quarterly highlights

Quarterly highlights
USD millionsQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025
Period ended30 Sep 202630 Jun 202631 Mar 202631 Dec 2025
Revenue (derived)5,1164,2913,6053,884
Operating income (derived)2,0481,294643880
Net income (derived)1,9491,297727845
Diluted earnings per share18.4512.236.75n/a
Operating cash flow (derived)1,7838131,0791,171
Total assets44,40541,73140,86940,559

Regeneron Pharmaceuticals major shareholders

Regeneron Pharmaceuticals major shareholders
HolderShare of classSharesFiled
Vanguard Capital Management7.4%7,660,81030 April 2026

Regeneron Pharmaceuticals 10-K and SEC filings

Regeneron Pharmaceuticals 10-K and SEC filings
FiledFormTypeDescription
30 October 202610-QQuarterly reportQuarterly report
30 October 20268-KCurrent reportCurrent report
6 October 20268-KCurrent reportFORM 8-K
30 September 20268-KCurrent reportFORM 8-K
30 July 202610-QQuarterly reportQuarterly report
30 July 20268-KCurrent reportCurrent report
6 July 20268-KCurrent reportFORM 8-K
17 June 20268-KCurrent reportFORM 8-K

Common questions

What was Regeneron Pharmaceuticals' revenue in fiscal 2025?

Regeneron Pharmaceuticals reported $14.3 billion in revenue for fiscal 2025, the year ended 31 December 2025, up 1.0% from fiscal 2024.

What was Regeneron Pharmaceuticals' net income in fiscal 2025?

Regeneron Pharmaceuticals reported net income of $4.5 billion for fiscal 2025, the year ended 31 December 2025, up 2.1% from fiscal 2024. Diluted earnings per share were $41.48.

What was Regeneron Pharmaceuticals' free cash flow in fiscal 2025?

Regeneron Pharmaceuticals had $4.1 billion in free cash flow in fiscal 2025. Operating cash flow was $5.0 billion and capital expenditure was $898 million.

What were Regeneron Pharmaceuticals' total assets at the end of fiscal 2025?

Regeneron Pharmaceuticals reported total assets of $40.6 billion at the end of fiscal 2025, the year ended 31 December 2025.

How much Regeneron Pharmaceuticals history do I get?

Every account gets the full history, annual and quarterly, with first reported values and as of dates.